- TLDR Biotech
- Archive
- Page -6
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | December 17 - 18, 2025
🧬 Novo Nordisk files CagriSema (cagrilintide/semaglutide) for FDA approval targeting amylin-GLP-1 pathways in obesity, Athira Pharma + Sermonix Pharmaceuticals partner on breast cancer drug lasofoxifene for $34.9M equity + $100M milestones, Insilico Medicine aims for $292M IPO on the Hong Kong Stock Exchange, AI-powered drug discovery and development platform, Novartis builds largest global R&D hub outside Switzerland in India with 9,000 employees, Orum Therapeutics raises $100M funding, degrader-antibody conjugates for cancer treatment, Syremis Therapeutics launches with $165M Series A to develop M1/M4 muscarinic drug rivaling BMS’s Cobenfy for schizophrenia
Biotech & Pharma Updates | December 16 - 17, 2025
🧬 Addition Therapeutics emerges from stealth with $100M to develop novel gene therapies for chronic + rare diseases, Merck & Co.'s Keytruda (pembrolizumab) plus Padcev hits Ph3 endpoints in perioperative muscle-invasive bladder cancer treatment, Boehringer Ingelheim + Galux partner on AI-driven precision protein design research using GaluxDesign platform, Alnylam Pharmaceuticals invests $250M to expand RNAi manufacturing facility using new enzymatic ligation technology, Cascade Pharmaceuticals raises $46M Series B for phase III trials and pipeline development, BMS + Harbour BioMed collaborate on multi-specific antibodies - $90M upfront + $1.035B milestones, Johnson & Johnson's Rybrevant Faspro (amivantamab) receives FDA approval as first subcutaneous EGFR-targeted non-small cell lung cancer therapy
Biotech & Pharma Updates | December 15 - 16, 2025
🧬 Genentech + Caris Life Sciences collaborate on AI-driven cancer target discovery with $25M upfront + $1.1B milestones, Link Cell Therapies debuts with $60M series A for logic-gated CAR-T platform, Allink Biotherapeutics raises $47M Series A extension to advance ADC clinical programs, Ambros Therapeutics launches with $125M Series A to advance Italian non-opioid pain drug neridronate, Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for $315M, Fosun Pharma acquires 53% stake in Green Valley Pharmaceuticals for $200M - reviving Alzheimer's drug GV-971, GSK's Exdensur (depemokimab) wins FDA approval for severe eosinophilic asthma treatment following Ph3 trials, Pfizer plans 15 obesity trials next year to replace $17 billion patent cliff revenue loss
Biotech & Pharma Updates | December 14 - 15, 2025
🧬 Chai Discovery raises $130M Series B for AI-powered drug design suite development, XOMA Royalty acquires Generation Bio for $4.29 per share plus contingent value rights, Novo Nordisk launches Ozempic in India - pricing lowest dose at $24 weekly for diabetes market, Link Cell Therapies raises $60M Series A to develop next-gen CAR-T therapies, Kyverna Therapeutics' miv-cel CAR-T therapy meets Ph2 endpoints for stiff person syndrome, Adaptive Biotechnologies + Pfizer partner on TCR platform for rheumatoid arthritis in up to $890M biobucks deal, Sanofi in-licenses Adel Therapeutics Alzheimer's antibody ADEL-Y01 for $80M upfront and up to $1.04B total deal value, FDA approves AstraZeneca and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) for first-line HER2-positive metastatic breast cancer
Biotech & Pharma Updates | December 11 - 14, 2025
🧬 William Blair predicts biotech sector will outperform 2021-24 bear markets in 2026 outlook, CIRM approves $160M funding for regenerative medicine research and clinical trials, Zealand Pharma seeks brain-targeting obesity treatment partners - explores shuttle technology collaborations, Tenaya Therapeutics raises $60M public offering to develop heart disease therapies, Sobi acquires Arthrosi Therapeutics for $950M upfront - adding gout treatment pozdeutinurad to pipeline, Anixa Biosciences' alpha-lactalbumin vaccine shows positive Ph1 results for triple-negative breast cancer prevention, Innovent Biologics' mazdutide (GLP-1/glucagon dual agonist) shows significant weight loss in Ph1b obesity trial in Chinese adolescents, FDA expands Johnson & Johnson's Akeega (abiraterone/niraparib) approval for BRCA2-mutated metastatic castration-sensitive prostate cancer
![The $4 Million Problem [Guest Post]](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=800,height=421,fit=scale-down,onerror=redirect/uploads/publication/thumbnail/5a180b8a-b34c-48db-a2ed-64c17f43d4d9/landscape_Screenshot_2025-11-27_at_10.21.52_PM.png)
Biotech & Pharma Updates | December 10 - 11, 2025
🧬 Zealand Pharma + OTR Therapeutics partner on metabolic disease therapeutics with $20M upfront + $2.5B biobucks, Amgen's Uplizna (inebilizumab) wins FDA approval for generalized myasthenia gravis targeting CD19-positive B cells, Xcell Biosciences + Culture Biosciences partner to advance cell therapy quality through AI and machine learning, Eli Lilly's retatrutide (triple hormone receptor agonist) achieves 26.6% weight loss in Ph3 obesity trial, Aukera Therapeutics emerges from stealth with CHF 4.5M ($5.63M) funding for neurological RAPTOR inhibitor development, Prolynx raises $70M Series A for longer-lasting obesity drugs with less frequent dosing, European legislators agree on major pharma policy overhaul reducing drug exclusivity periods + strengthening supply chains
Biotech & Pharma Updates | December 9 - 10, 2025
🧬 FDA approves Fondazione Telethon's gene therapy for Wiskott-Aldrich syndrome - first gene therapy approved from a non-profit sponsor, Formation Bio + Lynk Pharmaceuticals partner on TYK2 inhibitor LNK01006 with $605M total deal value, InduPro Therapeutics + Sanofi partner on bispecific PD-1 agonist for autoimmune disorders with undisclosed equity investment, Roche's giredestrant (oral SERD) shows 30% risk reduction in Ph3 early estrogen receptor-positive breast cancer trial, PsiThera raises $47.5M Series A for AI-designed oral drugs for immune conditions, Great Point Partners acquires majority stake in Lenis Group - specialty pharmaceutical distributor in Central and Eastern Europe, FDA finalizes guidance on promotional materials for biologics and biosimilars requiring accurate + non-misleading advertising
Biotech & Pharma Updates | December 8 - 9, 2025
🧬 Pfizer vaults another attempt towards an obesity pill by partnering with YaoPharma on Ph1 asset YP05002 - $150M upfront + $1.94B biobucks, Roche's Gazyvaro (obinutuzumab) wins EU approval for lupus nephritis treatment following Ph3 trial success, Cellular Origins raises $40M Series A for cell therapy manufacturing automation platform, Eli Lilly selects Alabama for $6B API facility to produce weight-loss pill orforglipron, Bora Pharmaceuticals + Corealis Pharma form strategic alliance for end-to-end oral solid dose development and production, Sidera Bio raises $109M Series A, developing obesity GLP-1/GIP/FGF21 triple agonist, BioNTech and Bristol Myers Squibb report positive Ph2 data for pumitamig in triple-negative breast cancer, Novartis' ianalumab hits Ph3 endpoints in immune thrombocytopenia
Biotech & Pharma Updates | December 7 - 8, 2025
🧬 Mirum Pharmaceuticals acquires Bluejay Therapeutics for $620M to gain hepatitis D drug brelovitug nearing Phase 3 results, Dr. Reddy's + Immutep partner on phase 3 immunotherapy eftilagimod alpha - $20M upfront + $349.5M biobucks, Biogen + Stoke Therapeutics' zorevunersen shows 82% seizure reduction in Dravet syndrome patients through 24 months, Dyne Therapeutics' zeleciment rostudirsen (z-rostudirsen) shows strong Ph1/2 results in Duchenne muscular dystrophy, Pan Cancer T raises €10M ($11.64M) funding for TCR-T cell therapy trial, China launches first private insurance formulary featuring drugs from big pharma, Singapore allocates $28.5 billion over five years for deep tech research including AI and biotechnology development
Biotech & Pharma Updates | December 4 - 7, 2025
🧬 German court grants Halozyme preliminary injunction halting Merck & Co.'s Keytruda SC launch activities over patent dispute, Immortal Dragons + Etheros partner on aging disease drugs targeting oxidative stress with fullerene derivatives, FDA approves Ayrmid's Omisirge (omidubicel-onlv) as first cell therapy for severe aplastic anemia treatment, FDA lifts partial clinical hold on Vanda Pharmaceuticals' motion sickness drug tradipitant following dispute resolution, Protara raises $75M public offering to fund TARA-002 clinical development program, Vertex's Casgevy (exagamglogene autotemcel) hits Ph3 goals in children with sickle cell disease and beta thalassemia, Pfizer's Hympavzi shows Ph3 success reducing bleeding in hemophilia A and B patients with inhibitors
Biotech & Pharma Updates | December 3 - 4, 2025
🧬 Denali Therapeutics + Royalty Pharma strike $275M financing deal for Hunter syndrome drug tividenofusp alfa, OTR Therapeutics raises $100M Series A for advancing early-stage innovations into "globally impactful" therapies, Paradigm Health raises $78M Series B for AI-powered clinical trials platform expansion, AstraZeneca + Neurimmune partner on amyloidosis antibody NI009 in up to $780M deal, FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory marginal zone lymphoma, Buckland Group launches Quvara Medical CDMO after acquiring Becton Dickinson's U.K. manufacturing facility